| Company Name |
Novartis (Taiwan) Co., Ltd. |
| Protocol Number |
CZOL446ETW03 |
| Title of Study |
Quality of Life Evaluation of Breast Cancer Patients with Bone Metastasis after Administration of Zometa (zoledronic acid) |
| Primary Objective |
The primary study objective is to evaluate the QoL score change after administration of Zometa® for 96 weeks. |
| Number of Sites |
13 |
| Period of Study |
from 2008-07-23 to 2012-12-31 |
| Number of Patients |
480 |
| IRB Approval Date |
06-Jun-2008 |
| Publication Plan / Date |
30-May-2013 |
